<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - IMATINIB</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>IMATINIB</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of chronic myeloid leukaemia in chronic phase after failure with interferon alfa</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg once daily, increased if necessary up to 800 mg daily in 2 divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of chronic myeloid leukaemia in accelerated phase, or in blast crisis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                600 mg once daily, then increased if necessary up to 800 mg daily in 2 divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of newly diagnosed acute lymphoblastic leukaemia (in combination with other chemotherapy)</span>,
                <span class="indication">Monotherapy for relapsed or refractory acute lymphoblastic leukaemia</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                600 mg once daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of c-kit (CD117)-positive unresectable or metastatic malignant gastro-intestinal stromal tumours (GIST)</span>,
                <span class="indication">Adjuvant treatment following resection of c-kit (CD117)-positive GIST, in patients at significant risk of relapse</span>,
                <span class="indication">Treatment of myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangement</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg once daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of unresectable dermatofibrosarcoma protuberans</span>,
                <span class="indication">Recurrent or metastatic dermatofibrosarcoma protuberans, in patients who cannot have surgery</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                800 mg daily in 2 divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of advanced hypereosinophilic syndrome and chronic eosinophilic leukaemia</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                100&#8211;400 mg once daily.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Imatinib is a tyrosine kinase inhibitor.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid unless potential benefit outweighs risk.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Max. 400&#8239;mg daily; reduce dose further if not tolerated.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Maximum starting dose 400&#8239;mg daily if creatinine clearance less than 60&#8239;mL/minute; reduce dose further if not tolerated.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, appetite changes, arthralgia, ascites, conjunctivitis, constipation, cough, cramps, diarrhoea, dizziness, dry eyes, dry mouth, dry skin, dyspnoea, epistaxis, fatigue, flatulence, flushing, gastro-oesophageal reflux, haemorrhage, headache, hypoaesthesia, increased lacrimation, influenza-like symptoms, insomnia, oedema, paraesthesia, photosensitivity, pleural effusion, pruritus, pulmonary oedema, rash, sweating, taste disturbance, visual disturbances, weight changes,
              </p>
              <p>
                <strong>uncommon:</strong> Acute respiratory failure, anxiety, cold extremities, cough, depression, drowsiness, dysphagia, electrolyte disturbances, gastric ulceration, gout, gynaecomastia, haematoma, hearing loss, heart failure, hepatic dysfunction, hypertension, hypotension, impaired memory, irregular menstruation, menorrhagia, migraine, palpitation, pancreatitis, peripheral neuropathy, renal failure, sexual dysfunction, skin hyperpigmentation, syncope, tachycardia, tinnitus, tremor, urinary frequency, vertigo,
              </p>
              <p>
                <strong>rare:</strong> Angina, angioedema, arrhythmia, aseptic necrosis of bone, atrial fibrillation, cataract, confusion, convulsions, exfoliative dermatitis, gastro-intestinal perforation, glaucoma, haemolytic anaemia, hepatic failure, hepatic necrosis, increased intracranial pressure, inflammatory bowel disease, intestinal obstruction, myocardial infarction, myopathy, pulmonary fibrosis, pulmonary hypertension, rhabdomyolysis, Stevens-Johnson syndrome,
              </p>
              <p>
                <strong>notKnown:</strong> Alopecia, bone-marrow suppression, drug rash with eosinophilia and systemic symptoms (DRESS), growth retardation in children, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Tablets may be dispersed in water or apple juice.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients or carers should be given advice on how to administer imatinib tablets.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA70</h3>
              <p outputclass="title">Imatinib for chronic myeloid leukaemia (October 2003)</p> <p>Imatinib is recommended as first-line treatment for Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase and as an option for patients presenting in the accelerated phase or with blast crisis, provided that imatinib has not been used previously.</p><xref format="html" href="http://www.nice.org.uk/TA70">www.nice.org.uk/TA70</xref>
                <a href="http://www.nice.org.uk/TA70" target="_blank">www.nice.org.uk/TA70</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA86</h3>
              <p outputclass="title">Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (October 2004)</p> <p>Imatinib 400&#8239;mg daily is recommended as first-line management of KIT (CD117)-positive unresectable or metastatic, or both, gastro-intestinal stromal tumours. Continued therapy is recommended only if a response to initial treatment [as defined by Southwest Oncology Group criteria available at <xref format="html" href="http://www.nice.org.uk/TA86">www.nice.org.uk/TA86</xref>] is achieved within 12 weeks. Patients who have responded should be assessed at 12-week intervals. Discontinue if tumour ceases to respond.</p><xref format="html" href="http://www.nice.org.uk/TA86">www.nice.org.uk/TA86</xref>
                <a href="http://www.nice.org.uk/TA86" target="_blank">www.nice.org.uk/TA86</a>
                <a href="http://www.nice.org.uk/TA86" target="_blank">www.nice.org.uk/TA86</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA209</h3>
              <p outputclass="title">Imatinib for the treatment of unresectable and/&#8239;or metastatic gastro-intestinal stromal tumours (November 2010)</p> <p>Imatinib 600&#8239;mg daily or 800&#8239;mg daily is <b>not</b> recommended for unresectable or metastatic, or both, gastro-intestinal stromal tumours whose disease has progressed after treatment with imatinib 400&#8239;mg daily.</p><xref format="html" href="http://www.nice.org.uk/TA209">www.nice.org.uk/TA209</xref>
                <a href="http://www.nice.org.uk/TA209" target="_blank">www.nice.org.uk/TA209</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA241</h3>
              <p outputclass="title">Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)</p> <p>High-dose imatinib is <b>not </b>recommended for the treatment of chronic, accelerated or blast-crisis phase Philadelphia-chromosome-positive CML that is resistant to standard-dose imatinib.</p><xref format="html" href="http://www.nice.org.uk/TA241">www.nice.org.uk/TA241</xref>
                <a href="http://www.nice.org.uk/TA241" target="_blank">www.nice.org.uk/TA241</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA251</h3>
              <p outputclass="title">Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)</p> <p>Standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML).</p><xref format="html" href="http://www.nice.org.uk/TA251">www.nice.org.uk/TA251</xref>
                <a href="http://www.nice.org.uk/TA251" target="_blank">www.nice.org.uk/TA251</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA326</h3>
              <p outputclass="title">Imatinib for the adjuvant treatment of gastro-intestinal stromal tumours (November 2014)</p> <p>Imatinib is recommended as an option for adjuvant treatment of adult patients who are at high risk of relapse after surgery for KIT (CD117)-positive gastro-intestinal stromal tumours, as defined by the Miettinen 2006 criteria (based on tumour size, location, and mitotic rate), for up to 3 years.</p> <p>Patients currently receiving treatment initiated within the NHS with imatinib that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.</p><xref format="html" href="http://www.nice.org.uk/TA326">www.nice.org.uk/TA326</xref>
                <a href="http://www.nice.org.uk/TA326" target="_blank">www.nice.org.uk/TA326</a>
            </section>
      </section>

      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Risks of incorrect dosing of oral anti-cancer medicines</h3>
              <p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>
            <li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>
            <li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>
            </ul>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiac disease
          </li>
          <li>
            history of renal failure
          </li>
          <li>
            risk factors for heart failure
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended). Effective contraception required during treatment.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor for gastrointestinal haemorrhage.</p><p>Monitor complete blood counts regularly.</p><p>Monitor for fluid retention.</p><p>Monitor liver function.</p><p>Monitor growth in children (may cause growth retardation).</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of IMATINIB</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75630"><a href="../medicinalForm/PHP75630.html" data-target="#PHP75630" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
